Corrects EPS in Key Details table to $0.60 from -$0.60
Overview
Israel cancer immunotherapy firm's Q4 revenue beat analyst expectations
Company reported Q4 net profit, reversing previous year's loss
Cash position strengthened through AstraZeneca deal, extending runway into 2029
Outlook
Compugen expects cash balances to fund operations into 2029
Company anticipates MAIA-ovarian interim analysis in Q1 2027
Compugen advancing Phase 1 trial of GS-0321 licensed to Gilead
Result Drivers
ASTRAZENECA DEAL - Compugen monetized a portion of rilvegostomig royalties, strengthening cash position and extending runway into 2029
CLINICAL TRIAL EXPANSION - Initiated new trials for COM701 and GS-0321, expanding global clinical trial footprint
CLINICAL PRESENTATIONS - Presented COM701 and GS-0321 updates at ESMO and SITC 2025, supporting ongoing trials
Company press release: ID:nPn5ZZ05ya
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $67.33 mln | $1.36 mln (3 Analysts) |
Q4 EPS | $0.60 | ||
Q4 Net Income | $56.85 mln | ||
Q4 Gross Profit | $63.80 mln | ||
Q4 Operating Expenses | $7.75 mln | ||
Q4 Operating Income | $56.04 mln |
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Compugen Ltd is $4.00, about 121% above its February 27 closing price of $1.81
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)